Skip to main content

Belviq News

FDA Medwatch Alert: Drug Safety Communication: Belviq, Belviq XR (lorcaserin) by Eisai - FDA Requests Withdrawal of Weight-Loss Drug

ISSUE: FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased ...

FDA Medwatch Alert: Drug Safety Communication: Belviq, Belviq XR (lorcaserin) - Due to Possible Increased Risk of Cancer

ISSUE: The FDA is alerting the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine Belviq, Belviq XR (lorcaserin). ...

Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of Belviq XR (lorcaserin HCl) Extended-Release Tablets

WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ – Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight)

Belviq patient information at Drugs.com